VIVAC forskargrupp: Vacciner och immunterapier mot virus och cancer – Matti Sällberg

Article: CELL HOST & MICROBE. 2023;31(6):928-936.e4

Memory profiles distinguish cross-reactive and virus-specific T cell immunity to mpox.

Adamo S; Gao Y; Sekine T; Mily A; Wu J; Storgärd E; Westergren V; Filén F; Treutiger C-J; Sandberg JK; Sällberg M; Bergman P; Llewellyn-Lacey S; Ljunggren H-G; Price DA; Ekström A-M; Sette A; Grifoni A; Buggert M

Journal article: VACCINE INSIGHTS. 2023;02(05):167-173

OPENCORONA: lessons learned from a pandemic vaccine consortium

Sällberg M; Gidlund E-K

Article: GUT. 2023;72(6):1186-1195

Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections.

Burm R; Maravelia P; Ahlen G; Ciesek S; Caro Perez N; Pasetto A; Urban S; Van Houtte F; Verhoye L; Wedemeyer H; Johansson M; Frelin L; Sällberg M; Meuleman P

Preprint: BIORXIV. 2023

Phosphatidylinositol 4-kinase III alpha governs cytoskeletal organization for invasiveness of liver cancer cells

Tran CS; Kersten J; Breinig M; Yan J; Poth T; Colasanti O; Riedl T; Faure-Dupuy S; Diehl S; Verhoye L; Li T-F; Lingemann M; Schult P; Ahlén G; Frelin L; Kühnel F; Breuhahn K; Vondran FWR; Meuleman P; Heikenwälder M; Schirmacher P; Sällberg M; Bartenschlager R; Laketa V; Tschaharganeh DF; Lohmann V

Article: MOLECULAR THERAPY. 2023;31(2):387-397

Accelerated DNA vaccine regimen provides protection against Crimean-Congo hemorrhagic fever virus challenge in a macaque model.

Hawman DW; Meade-White K; Leventhal S; Appelberg S; Ahlén G; Nikouyan N; Clancy C; Smith B; Hanley P; Lovaglio J; Mirazimi A; Sällberg M; Feldmann H

Review: IMMUNO-ONCOLOGY AND TECHNOLOGY. 2022;16:100099

ATMP development and pre-GMP environment in academia: a safety net for early cell and gene therapy development and manufacturing.

Silva DN; Chrobok M; Ahlén G; Blomberg P; Sällberg M; Pasetto A

Article: EMBO MOLECULAR MEDICINE. 2022;14(10):e15821

A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells.

Appelberg S; Ahlén G; Yan J; Nikouyan N; Weber S; Larsson O; Höglund U; Aleman S; Weber F; Perlhamre E; Apro J; Gidlund E-K; Tuvesson O; Salati S; Cadossi M; Tegel H; Hober S; Frelin L; Mirazimi A; Sällberg M

Article: JOURNAL OF VIROLOGY. 2022;96(3):e0156821-e01521

Nucleoside-Modified mRNA Vaccines Protect IFNAR-/- Mice against Crimean-Congo Hemorrhagic Fever Virus Infection.

Appelberg S; John L; Pardi N; Végvári Á; Bereczky S; Ahlén G; Monteil V; Abdurahman S; Mikaeloff F; Beattie M; Tam Y; Sällberg M; Neogi U; Weissman D; Mirazimi A

Article: FRONTIERS IN IMMUNOLOGY. 2022;13:896242

Process Development for Adoptive Cell Therapy in Academia: A Pipeline for Clinical-Scale Manufacturing of Multiple TCR-T Cell Products.

Silva DN; Chrobok M; Rovesti G; Healy K; Wagner AK; Maravelia P; Gatto F; Mazza M; Mazzotti L; Lohmann V; Sällberg Chen M; Sällberg M; Buggert M; Pasetto A

Preprint: BIORXIV. 2021

Longitudinal characterization of humoral and cellular immunity in hospitalized COVID-19 patients reveal immune persistence up to 9 months after infection

Sandberg JT; Varnaitė R; Christ W; Chen P; Muvva J; Maleki K; García M; Dzidic M; Folkesson E; Skagerberg M; Ahlén G; Frelin L; Sällberg M; Eriksson L; Rooyackers O; Sönnerborg A; Buggert M; Björkström N; Aleman S; Strålin K; Klingström J; Ljunggren H-G; Blom K; Gredmark-Russ S; The Karolinska COVID-19 Study Group

Article: NATURE MICROBIOLOGY. 2021;6(2):187-195

A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a Cynomolgus macaque model.

Hawman DW; Ahlén G; Appelberg KS; Meade-White K; Hanley PW; Scott D; Monteil V; Devignot S; Okumura A; Weber F; Feldmann H; Sällberg M; Mirazimi A

Article: JOURNAL OF INFECTIOUS DISEASES. 2021;223(1):128-138

Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections.

Maravelia P; Frelin L; Ni Y; Caro Pérez N; Ahlén G; Jagya N; Verch G; Verhoye L; Pater L; Johansson M; Pasetto A; Meuleman P; Urban S; Sällberg M

Article: MOLECULAR & CELLULAR PROTEOMICS. 2021;20:100159

Metabolic Perturbation Associated With COVID-19 Disease Severity and SARS-CoV-2 Replication.

Krishnan S; Nordqvist H; Ambikan AT; Gupta S; Sperk M; Svensson-Akusjärvi S; Mikaeloff F; Benfeitas R; Saccon E; Ponnan SM; Rodriguez JE; Nikouyan N; Odeh A; Ahlén G; Asghar M; Sällberg M; Vesterbacka J; Nowak P; Végvári Á; Sönnerborg A; Treutiger CJ; Neogi U

Article: CLINICAL & TRANSLATIONAL IMMUNOLOGY. 2021;10(7):e1306

SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation.

Sandberg JT; Varnaitė R; Christ W; Chen P; Muvva JR; Maleki KT; García M; Dzidic M; Folkesson E; Skagerberg M; Ahlén G; Frelin L; Sällberg M; Eriksson LI; Rooyackers O; Sönnerborg A; Buggert M; Björkström NK; Aleman S; Strålin K; Klingström J; Ljunggren H-G; Blom K; Gredmark-Russ S; Karolinska COVID‐19 Study Group

Article: GUT. 2020;69(12):2203-2213

Evidence for B cell maturation but not trained immunity in uninfected infants exposed to hepatitis C virus.

Lutckii A; Strunz B; Zhirkov A; Filipovich O; Rukoiatkina E; Gusev D; Lobzin Y; Fischler B; Aleman S; Sällberg M; Björkström NK

Article: JOURNAL OF IMMUNOLOGY. 2020;205(9):2437-2446

Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients.

Varnaitė R; García M; Glans H; Maleki KT; Sandberg JT; Tynell J; Christ W; Lagerqvist N; Asgeirsson H; Ljunggren H-G; Ahlén G; Frelin L; Sällberg M; Blom K; Klingström J; Gredmark-Russ S

Article: BMJ OPEN. 2020;10(9):e035996

Sick leave and disability pension in patients with chronic hepatitis C compared with a matched general population: a nationwide register study.

Büsch K; Hansson F; Holton M; Lagging M; Westin J; Kövamees J; Sällberg M; Söderholm J

Letter: JOURNAL OF VIROLOGY. 2020;94(18):e01279-e01220

The SARS-CoV-2 N Protein Is a Good Component in a Vaccine.

Ahlén G; Frelin L; Nikouyan N; Weber F; Höglund U; Larsson O; Westman M; Tuvesson O; Gidlund E-K; Cadossi M; Appelberg S; Mirazimi A; Sällberg M; OPENCORONA Consortium

Article: HUMAN VACCINES & IMMUNOTHERAPEUTICS. 2020;16(2):251-268

Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance.

Whitacre DC; Peters CJ; Sureau C; Nio K; Li F; Su L; Jones JE; Isogawa M; Sallberg M; Frelin L; Peterson DL; Milich DR

Review: FRONTIERS IN IMMUNOLOGY. 2020;11:552

Liver, Tumor and Viral Hepatitis: Key Players in the Complex Balance Between Tolerance and Immune Activation.

Sällberg M; Pasetto A

Article: GUT. 2018;67(8):1525-1535

Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model.

Levander S; Holmström F; Frelin L; Ahlén G; Rupp D; Long G; Bartenschlager R; Sällberg M

Visa fler

VIVAC forskargrupp: Vacciner och immunterapier mot virus och cancer – Matti Sällberg

Publikationer

Utvalda publikationer

Finansiering

Finansiärer

Medarbetare och kontakt

Gruppledare

Alla medlemmar i gruppen